Last update 21 Nov 2024

Recombinant Staphylococcus Aureus(Escherichia Coli)(Chongqing Yuanlun Biotechnology)

Overview

Basic Info

Drug Type
Prophylactic vaccine
Synonyms-
Target-
Mechanism
Immunostimulants
Therapeutic Areas
Infectious Diseases
Active Indication
Staphylococcus Aureus Infections
Inactive Indication
Sepsis
Originator Organization
Third Military Medical UniversityThird Military Medical UniversityChongqing Yuanlun Biotechnology Co., Ltd.Chongqing Yuanlun Biotechnology Co., Ltd.
Active Organization
Chengdu Olymvax Biopharmaceuticals, Inc.Chengdu Olymvax Biopharmaceuticals, Inc.Third Military Medical UniversityThird Military Medical University
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Related

5
Clinical Trials associated with Recombinant Staphylococcus Aureus(Escherichia Coli)(Chongqing Yuanlun Biotechnology)
CTR20221329 / RecruitingPhase 3
评价重组金黄色葡萄球菌疫苗（大肠杆菌）用于骨科手术目标人群中的保护效力、安全性和免疫原性的多中心、随机、双盲、安慰剂对照的Ⅲ期临床试验
[Translation] A multicenter, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the protective efficacy, safety and immunogenicity of recombinant Staphylococcus aureus vaccine (Escherichia coli) in the target population of orthopedic surgery
ChiCTR2200066259 / CompletedPhase 2IIT
A multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and immunogenicity of recombinant Staphylococcus aureus vaccine (E. coli) in the target population undergoing orthopaedic surgery
CTR20190552 / CompletedPhase 1
单中心、开放性Ib期临床试验评价重组金黄色葡萄球菌疫苗（大肠杆菌）不同免疫程序下的安全性和初步免疫原性
[Translation] A single-center, open-label phase Ib clinical trial to evaluate the safety and preliminary immunogenicity of recombinant Staphylococcus aureus vaccine (Escherichia coli) under different immunization schedules
100 Clinical Results associated with Recombinant Staphylococcus Aureus(Escherichia Coli)(Chongqing Yuanlun Biotechnology)
Login to view more data
100 Translational Medicine associated with Recombinant Staphylococcus Aureus(Escherichia Coli)(Chongqing Yuanlun Biotechnology)
Login to view more data
100 Patents (Medical) associated with Recombinant Staphylococcus Aureus(Escherichia Coli)(Chongqing Yuanlun Biotechnology)
Login to view more data
100 Deals associated with Recombinant Staphylococcus Aureus(Escherichia Coli)(Chongqing Yuanlun Biotechnology)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Staphylococcus Aureus InfectionsPhase 3
CN
Chengdu Olymvax Biopharmaceuticals, Inc.Chengdu Olymvax Biopharmaceuticals, Inc.
29 Aug 2022
Staphylococcus Aureus InfectionsPhase 3
CN
Third Military Medical UniversityThird Military Medical University
29 Aug 2022
SepsisPreclinical
CN
Third Military Medical UniversityThird Military Medical University
14 Jun 2016
SepsisPreclinical
CN
Chengdu Olymvax Biopharmaceuticals, Inc.Chengdu Olymvax Biopharmaceuticals, Inc.
14 Jun 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free